loading
前日終値:
$19.65
開ける:
$20.04
24時間の取引高:
357.66K
Relative Volume:
0.87
時価総額:
$1.06B
収益:
-
当期純損益:
$-85.21M
株価収益率:
-10.87
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
-4.53%
1か月 パフォーマンス:
+7.24%
6か月 パフォーマンス:
-14.12%
1年 パフォーマンス:
-5.41%
1日の値動き範囲:
Value
$19.73
$21.29
1週間の範囲:
Value
$19.22
$21.89
52週間の値動き範囲:
Value
$13.30
$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
名前
Enliven Therapeutics Inc
Name
セクター
Healthcare (1168)
Name
電話
720-647-8519
Name
住所
6200 LOOKOUT ROAD, BOULDER
Name
職員
65
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
ELVN's Discussions on Twitter

ELVN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ELVN
Enliven Therapeutics Inc
20.53 1.06B 0 -85.21M -68.53M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
454.76 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
548.16 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
549.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.46 28.51B 3.81B -644.79M -669.77M -6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-16 開始されました Goldman Buy
2024-12-13 開始されました BTIG Research Buy
2024-09-09 開始されました H.C. Wainwright Buy
2024-06-11 開始されました Robert W. Baird Outperform
2024-04-09 開始されました Mizuho Buy
2023-03-29 開始されました Jefferies Buy
すべてを表示

Enliven Therapeutics Inc (ELVN) 最新ニュース

pulisher
Jun 18, 2025

Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 17, 2025

Enliven grosses $230M from stock sale - BizWest

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey

Jun 16, 2025
pulisher
Jun 16, 2025

Enliven Therapeutics Closes Public Offering - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Form 424B5 Enliven Therapeutics, - StreetInsider

Jun 16, 2025
pulisher
Jun 16, 2025

Enliven (ELVN) Gains Buy Rating from Goldman Sachs with $37 Price Target | ELVN Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell? - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven to sell $200M in stock after positive drug trial - BizWest

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics prices $200 million public offering - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics announces $200 million public offering - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow

Jun 13, 2025
pulisher
Jun 13, 2025

Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire

Jun 13, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 01, 2025
pulisher
Jun 01, 2025

BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World

May 31, 2025
pulisher
May 30, 2025

Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail

May 30, 2025
pulisher
May 30, 2025

Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 30, 2025
pulisher
May 28, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 25, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World

May 25, 2025
pulisher
May 22, 2025

Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq

May 22, 2025
pulisher
May 22, 2025

(ELVN) Proactive Strategies - news.stocktradersdaily.com

May 22, 2025
pulisher
May 22, 2025

Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia

May 22, 2025
pulisher
May 21, 2025

Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India

May 21, 2025

Enliven Therapeutics Inc (ELVN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Enliven Therapeutics Inc (ELVN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Jun 27 '25
Sale
20.91
3,250
67,956
23,000
$20.48
price down icon 1.20%
$36.01
price up icon 0.38%
$22.30
price up icon 5.47%
$96.96
price down icon 0.65%
$106.92
price down icon 0.50%
biotechnology ONC
$242.87
price down icon 0.89%
大文字化:     |  ボリューム (24 時間):